Award Data

DESCRIPTION (provided by applicant): There is a recognized need for development of protein capture tools that will reliably detect a variety of targets, over a broad range of concentrations, for use with human plasma and other complex sample mixtures for diagnostic and therapeutic applications. The products from our PEARL [Pathogen-Encoded Adaptable Receptor Library] technology will yield antibody ...

DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observations in depressed individuals, findings in animal models, and an understanding of changes in hypothalamic-pituitary-adrenal (HPA) axis regulation under chronic stress. This Fast Track proposal seeks ...

DESCRIPTION (provided by applicant): The objective of this research project is to develop, evaluate, and disseminate an Internet-based (web) application for SMART Recovery: Overcoming Addictions (OA). OA will be based on the four point cognitive-behavioral program for SMART Recovery (www.smartrecovery.org). The goal of the OA program is to help users learn cognitive and behavioral skills to abstai ...

DESCRIPTION (provided by applicant): Most cellular processes are regulated by reversible protein phosphorylation, which is controlled by protein kinases and phosphatases. Caldera Pharmaceuticals and MedChem Partners propose to develop new probes for characterizing transient protein complexes. MAPK pathways play important roles in cellular differentiation and survival. MAPKs are serine/threonine pr ...

DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. In Phase I, Caldera will demonstrate the feasibility of using its novel XRpro(R) technology to extract, concentrate, quantify, and characterize carcinogens from biological samples. This will also identify protein adduct biomarkers that are involved in critical carcinoge ...

DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a safe, cost-effective, off-the-shelf, and well characterized bone filler material based on plastics derived from blood plasma. Over 800,000 bone procedures are performed in the US per year, and with the aging US population, this number will only continue to grow. However, current materials, including autografts ...

DESCRIPTION (provided by applicant): Compact Membrane Systems, Inc. proposes to develop novel blood oxygenator membranes with enhanced blood biocompatibility. These will be used to enhance conventional cardio bypass surgery minimizing post operative effects. In addition, they will provide a key element for long term blood oxygenation associated with extracorporeal membrane oxygenation, acute respi ...

PTEN/Akt/mTORC 1and2 signal pathway is a critical regulator of cell survival, cell growth and proliferation, angiogenesis, cellular metabolism, cell migration and invasion and glucose uptake. A number of anticancer drugs in clinical trials are targeting this pathway. In Phase I, we will develop reliable, accurate, quantitative and sensitive multiplexed hybrid ELISA/qPCR assay (ELISA combined with ...

Antibody therapy offers treatment for a wide range of diseases and can extend the life of cancer patients, but the treatment cost is extremely expensive. as patent protection of some current antibodies will expire in coming years, there is an opportunity to develop generic and lower priced versions of these therapeutic biologics for the treatment of cancer. To accelerate the development of a gener ...

DESCRIPTION (provided by applicant): Influenza viruses are highly infectious RNA viruses that cause epidemic respiratory disease in the human population. There is an urgent unmet need for an influenza vaccine with greater potency, durability of antibody response, and strain-cross reactivity that can be developed more rapidly than conventional influenza virus. The recent epidemic spread of H1N1 and ...